Fruitamins Ltd to Establish Partnerships for Vivalue Globally

The design-idea behind Livaform is “what you see is what you get”. The tablets offer a one per day convenience with an all natural sweetness and flavor system.

Sep 26 2011 --- Fruitamins Ltd, UK-based global consulting company, and Vivalue Oy, Finnish self-care provider, have signed a global exclusive agency agreement for Vivalue’s new delivery system. Under the contact will Fruitamins Ltd establish partnerships globally for the Vivalue’s Livaform-product range. The markets in focus are EU, USA and Asia where Fruitamins has a solid base in the supplement and pharma-industries.

Fruitamins Ltd is a global consulting company registered in the United Kingdom with main market focus on Europe, United States and Asia. The company was founded by 4 industry professionals with years of experience in the supplements, food and pharma segments. Fruitamins Ltd works with B-2-B tasks globally for innovative and value added health and lifestyle products. Vivalue is a Finnish self-care provider behind the Livaform-range. Livaform is about self-care.

It is offering a selection of naturally vitamin and mineral based products to supplement a healthy diet. Food supplements are presented as functional themes where the forms reflect the origin of ingredients and taste. The design-idea behind Livaform is “what you see is what you get”. The tablets offer a one per day convenience with an all natural sweetness and flavor system.

The new delivery type is targeted the high-end market and life style consumers demanding convenience and health assurance in a normal balanced diet style. Livaform is formulated with stevia as the sweetener in the product by this anticipating the coming reform in the EU-legislation. The three first products, Daily Balance, Kids Balance and Immune Active are sold under license either under Livaform or other existing brands. The geographical focus is in EU, U.S. and Asia. A product pipe-line is defined and more variants are expected to enter the market in the near future.